



# Systematic review of functional outcome and quality of life after total pancreatectomy

L. Scholten<sup>1</sup> , T. F. Stoop<sup>1</sup>, M. Del Chiaro<sup>5</sup> , O. R. Busch<sup>1</sup>, C. van Eijck<sup>3</sup>, I. Q. Molenaar<sup>4</sup>, J. H. de Vries<sup>2</sup> and M. G. Besselink<sup>1</sup>, on behalf of the Dutch Pancreatic Cancer Group

<sup>1</sup>Department of Surgery, Cancer Centre Amsterdam, and <sup>2</sup>Department of Endocrinology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, <sup>3</sup>Department of Surgery, Erasmus Medical Centre, Rotterdam, and <sup>4</sup>Department of Surgery, University Medical Centre Utrecht, Utrecht, the Netherlands, and <sup>5</sup>Division of Surgical Oncology, Department of Surgery, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA

Correspondence to: Prof. Dr M. G. Besselink, Department of Surgery, G4-146-1, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands (e-mail: m.g.besselink@amsterdamumc.nl)

**Background:** Surgeons have traditionally been reluctant to perform total pancreatectomy because of concerns for brittle diabetes and poor quality of life (QoL). Several recent studies have suggested that outcomes following total pancreatectomy have improved, but a systematic review is lacking.

**Methods:** A systematic review was undertaken of studies reporting on outcomes after total pancreatectomy for all indications, except chronic pancreatitis. PubMed, EMBASE (Ovid), and Cochrane Library were searched (2005–2018). Endpoints included functional outcome and QoL.

**Results:** A total of 21 studies, including 1536 patients, fulfilled the eligibility criteria. During a median follow-up of 20.8 (range 1.5–96.0) months, 18.6 per cent (45 of 242 patients) were readmitted for endocrine-related morbidity, with associated mortality in 1.6 per cent (6 of 365 patients). No diabetes-related mortality was reported in studies including only patients treated after 2005. Symptoms related to exocrine insufficiency were reported by 43.5 per cent (143 of 329 patients) during a median follow-up of 15.9 (1.5–96.0) months. Overall QoL, reported by 102 patients with a median follow-up of 28.6 (6.0–66.0) months, using the EORTC QLQ-C30 questionnaire, showed a moderately reduced summary score of 76 per cent, compared with a general population score of 86 per cent ( $P = 0.004$ ).

**Conclusion:** Overall QoL after total pancreatectomy is affected adversely, in particular by the considerable impact of diarrhoea that requires better treatment. There is also room for improvement in the management of diabetes after total pancreatectomy, particularly with regards to prevention of diabetes-related morbidity.

Paper accepted 4 June 2019

Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.11296

## Introduction

The most common indication for total pancreatectomy is pancreatic cancer, but total pancreatectomy is increasingly performed for main-duct/mixed-type intraductal papillary mucinous neoplasm (IPMN)<sup>1–3</sup>. Total pancreatectomy for IPMN requires extensive counselling, as this is prophylactic surgery. Other indications for total pancreatectomy could be multifocal pancreatic disease (such as neuroendocrine tumours and renal cell cancer metastases) and technical difficulties, or patients with a very high risk of having a pancreatic anastomosis (for instance in arterial reconstruction)<sup>4–6</sup>.

Most surgeons have traditionally been reluctant to perform total pancreatectomy because of the associated postoperative morbidity and resulting lifelong insulin-

dependent brittle diabetes, with risk of severe hypoglycaemia and substantial impact on quality of life (QoL).

In recent years, several investigators have suggested that the role of total pancreatectomy in IPMN should be expanded as the postoperative management has improved<sup>7</sup>. Of note, a recent international survey<sup>8</sup> showed no consensus on the use of total pancreatectomy in patients with main-duct/mixed-type IPMN. This lack of consensus is likely to be related to concerns regarding total pancreatectomy-related diabetes and exocrine insufficiency. Others<sup>1,4</sup> have questioned whether any indication remains for an upfront total pancreatectomy in the current era of improved imaging.

Knowledge of long-term functional (endocrine and exocrine insufficiency) outcomes and QoL after total

pancreatectomy is therefore essential during preoperative counselling and shared decision-making. This systematic review focuses on short- and long-term functional outcomes after total pancreatectomy, and its impact on QoL.

## Methods

This systematic review was registered with PROSPERO (registration number CRD420016051093)<sup>9</sup> and performed in accordance with the PRISMA guidelines<sup>10</sup>.

### Search strategy

A systematic literature search was conducted in PubMed, EMBASE (Ovid), and the Cochrane Library for studies published from 1 January 2005 to 31 January 2018. This inclusion period was chosen because management of endocrine and exocrine insufficiency seems to have improved in recent years<sup>11</sup>. The main search term was 'total pancreatectomy'. The full search strategy is shown in *Table S1* (supporting information). Restrictions on English language and studies older than 13 years (arbitrary cut-off) were applied. After excluding duplicates, studies were screened by two authors independently, according to the eligibility criteria by title, abstract and full text. The final decision on eligibility was made by consensus.

### Eligibility criteria

Studies of at least ten patients reporting on functional outcomes and QoL after total pancreatectomy were considered eligible. Studies or subgroups where more than 10 per cent of patients had undergone total pancreatectomy for chronic pancreatitis were excluded unless results were given separately. Benign indications with no further description were considered as chronic pancreatitis. Conference abstracts and review articles were also excluded. When there were overlapping cohorts, only unique results were used. If there were overlapping outcomes between these cohorts, the largest study was chosen for analysis.

### Definitions

Total pancreatectomy was defined as removal of the entire pancreas, with or without splenectomy, performed via either an open or minimally invasive technique. Primary total pancreatectomy was defined as elective total pancreatectomy (planned before surgery as well as decided during the operation), and emergency total pancreatectomy as surgery performed as a result of trauma. Urgent completion total pancreatectomy was defined as emergency total

pancreatectomy for postoperative complications after pancreatoduodenectomy, whereas elective completion total pancreatectomy was performed mostly for recurrence in the remnant pancreas.

Endocrine insufficiency was defined as diabetes after total pancreatectomy, classified by the WHO<sup>12</sup> and the American Diabetes Association<sup>13</sup> as one of the causes of pancreatogenic (type 3c) diabetes. Exocrine insufficiency was defined as inadequate pancreatic enzyme function, with or without related symptoms, that required enzyme substitution.


Where only readmissions were reported, these were not defined as complications to avoid underestimation of diabetes-related morbidity. Invasive or malignant IPMNs were grouped under carcinomas as 'invasive IPMN'. When studies did not report the grade of dysplasia, the IPMNs were grouped as 'potentially malignant'. When studies presented only the minimum duration of follow-up, that value was chosen to calculate the pooled weighted median. When studies presented the maximum follow-up or the range, the half of this value was used to calculate the pooled weighted median. The postoperative period was defined as a maximum of 90 days after surgery.

### Extracted data

The following data were extracted per study by two authors: first author, country, year of publication, study design, age, sex, diagnosis/indication for surgery, duration of follow-up, number of patients undergoing total pancreatectomy, and outcomes of exocrine and endocrine insufficiency and QoL. Two authors cross-checked all data independently. Corresponding authors of the included studies were contacted where there was missing or insufficient data. The European Organization for Research and Treatment in Cancer Quality of Life Questionnaire Cancer (EORTC QLQ-C30) global health status, functioning and symptom scores were determined, and differences with the general population calculated. Clinically important differences were categorized and defined according to Osoba *et al.*<sup>14</sup>: less than 5 per cent, no change; 5–10 per cent, a little change; 10–20 per cent, moderate change; more than 20 per cent, very much change.

### Quality assessment

The methodological quality of the included studies was assessed by two authors independently, using the Newcastle–Ottawa Scale (NOS)<sup>15</sup>. Methodological quality was scored for 'selection of patients', 'comparability' and 'outcome of study participants', and was ranked with a maximum of 5 points. In this systematic review, the parts



QoL, quality of life.

of the NOS score ('selection of the non-exposed', 'outcome of interest' and 'comparability') were not applicable, because of its descriptive nature. In this study, cohort studies with a NOS score of 5 or higher were considered of high quality.

### Statistical analysis

Age, length of follow-up and QoL parameters from the different questionnaires are presented as mean(s.d.) and median (range) values. Categorical data are presented as frequencies and percentages. Overall follow-up values are presented as pooled weighted median. When included studies reported median (range) values, means(s.d.) values were calculated using statistical algorithms according to the method of Wan and colleagues<sup>16</sup> and Hozo and co-workers<sup>17</sup>.  $P < 0.050$  was considered statistically significant. Statistical analysis was performed using SPSS version 24 (IBM, Armonk, New York, USA).

### Results

The systematic search (Table S1, supporting information) identified 21 eligible studies, all cohort studies, comprising

1536 patients undergoing total pancreatectomy<sup>2,6,18–36</sup>. The PRISMA diagram of studies included in this systematic review is presented in Fig. 1. Most patients were men (52.6 per cent), and the median age was 65 years; the methodological quality was scored as high in 20 of the 21 studies (Table S2, supporting information).

### Surgical details

Of 1536 patients, indication for total pancreatectomy was pancreatic ductal adenocarcinoma (PDAC) in 806 patients (52.5 per cent) and IPMN in 454 patients (29.6 per cent); IPMN consisted of 227 patients (14.8 per cent) with non-invasive IPMN and 227 (14.8 per cent) with invasive IPMN (Table 1).

In 1254 patients (81.6 per cent), the type of total pancreatectomy (primary *versus* completion pancreatectomy) was described. Primary total pancreatectomy was performed in 1120 patients (89.3 per cent), of whom 1117 (99.7 per cent) had elective surgery and three (0.3 per cent) had emergency surgery. Completion total pancreatectomy was performed in 134 patients (10.7 per cent), electively in 110 (82.1 per cent) and as an emergency in 24 (17.9 per cent).

**Table 1** Diagnosis in patients who had a total pancreatectomy

Reference	n	Carcinomas	Non-carcinomas			Other
			Potentially malignant	Benign	CP*	
Barbier <i>et al.</i> <sup>18</sup>	56	PDAC (4)	IPMN (20)	–	1 (2)	Renal mets (2)
		Invasive IPMN (22)	NET (6)			
		Acinar cell carcinoma (1)				
Casadei <i>et al.</i> <sup>19†</sup>	20	PDAC (7)	IPMN (2)	–	1 (5)	Renal mets (2)
		Invasive IPMN (6)	NET (2)			
Casadei <i>et al.</i> <sup>20†</sup>	73	PDAC (38)	IPMN (15)	–	2 (3)§	Mets (3)
		Periampullary cancer (3)	NET (6)			Other (5)
						Serous cystic tumours (1)
Crippa <i>et al.</i> <sup>21†</sup>	65	PDAC (19)	IPMN (6)	SCA (1)	1 (2)	Renal mets (6)
		Invasive IPMN (25)	NET (6)			
		Periampullary cancer (1)				
Crippa <i>et al.</i> <sup>22†‡</sup>	29¶	Invasive IPMN (13)	IPMN (16)	–	0 (0)	–
Epelboym <i>et al.</i> <sup>23</sup>	77	PDAC (50)	IPMN (15)	SCA (1)	4 (5)§	Renal mets (1)
		Invasive IPMN (2)	NET (4)			
Fujino <i>et al.</i> <sup>24</sup>	36	PDAC (17)	NET (2)	Acute pancreatitis (1)	1 (3)	Mets (1)
		Invasive IPMN (14)				
Hartwig <i>et al.</i> <sup>6</sup>	434	PDAC (289)	IPMN (44)	SCN (4)	4 (0.9)§	Other (4)
		Invasive IPMN (31)	NET (28)			
		Adenosquamous carcinoma (8)				
		Acinar cell carcinoma (4)				
Hata <i>et al.</i> <sup>25</sup>	43	PDAC (21)	IPMN (11)	Solid pseudopapillary neoplasm (1)	1 (2)	Mets (3)
			NET (2)	SCN (1) AVM (3)		
Jamil <i>et al.</i> <sup>26</sup>	14	IPMN (9)	IPMN (5)	–	0 (0)	–
Kitagawa <i>et al.</i> <sup>27</sup>	10	Carcinoma (4)	IPMN (5)	Gastrinoma (1)	0 (0)	–
Müller <i>et al.</i> <sup>2‡</sup>	147	PDAC (78)	IPMN (12)	Cystic tumours (5)	13 (8.8)	Renal mets (9)
		Invasive IPMN (10)	NET (11)			
		Periampullary cancer (7)				
		Cystic tumour (2)				
Nikfarjam <i>et al.</i> <sup>28</sup>	15	Adenocarcinoma (13)	IPMN (1)	Cystadenoma (1)	0 (0)	–
Parsaik <i>et al.</i> <sup>29‡</sup>	97	PDAC (49)	Cystic neoplasm (7)	–	0 (0)	Other (14)
		Invasive IPMN (24)				
		Periampullary adenocarcinoma (3)				
Reddy <i>et al.</i> <sup>30</sup>	100	PDAC (100)	–	–	0 (0)	–
Shi <i>et al.</i> <sup>31</sup>	52	PDAC (43)	–	–	0 (0)	Renal mets (1)
		Invasive IPMN (4)				
		Adenosquamous carcinoma (1)				
		Acinar adenocarcinoma (1)				
Stauffer <i>et al.</i> <sup>32</sup>	47	PDAC (10)	IPMN (21)	–	2 (4)	Renal mets (1)
		Invasive IPMN (10)	NET (1)			Trauma (1)
		Cholangiocarcinoma (1)				
Suzuki <i>et al.</i> <sup>33</sup>	41	PDAC (13)	IPMN (5)	–	0 (0)	Renal mets (2)
		Invasive IPMN (20)	Intraductal tubulopapillary neoplasm (1)			

Table 1 Continued

Reference	n	Carcinomas	Non-carcinomas			Other
			Potentially malignant	Benign	CP*	
Takami <i>et al.</i> <sup>34,‡</sup>	33	PDAC (25)	IPMN (7)	–	1 (3)§	–
Watanabe <i>et al.</i> <sup>35</sup>	44	PDAC (20)	IPMN (2)	–	1 (2)§	Renal mets (1)
		Invasive IPMN (18)	NET (1)			
		Distal cholangiocarcinoma (1)				
Zakaria <i>et al.</i> <sup>36</sup>	103	PDAC (23)	IPMN (40)	Ampullary adenoma with IPMN (1)	8 (7.8)	Renal mets (1)
		Invasive IPMN (19)	NET (7)			
		Ampullary adenocarcinoma (1)				Trauma (1)
		Cholangiocarcinoma (1)				
		Sarcoma (1)				
Overall*	1536	1106 (72.0)	312 (20.3)	20 (1.3)	40 (2.6)	58 (3.8)

\*Values in parentheses are percentages. †No overlapping cohorts; used unique results and the biggest group in case of non-unique results; ‡subgroup used; §benign tumours (possible chronic pancreatitis (CP)); ¶after contacting author. PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm; NET, neuroendocrine tumour; mets, metastases; SCA, serous cystadenoma; SCN, serous cystic neoplasm; AVM, arteriovenous malformation.

## Endocrine insufficiency

Outcomes related to endocrine insufficiency after total pancreatectomy were reported in 19 studies<sup>2,6,18–24,26–33,35,36</sup>, including 809 patients, after a median follow-up of 20.8 (range 1.5–96.0) months. The endocrine-related morbidity rate was 25.9 per cent (112 of 432 patients). Ten studies<sup>18–24,32,33,35</sup>, including 299 patients, reported the number of prescribed insulin units per day (mean 27 units/day). Mean(s.d.) HbA1c levels at 6 and 12 months after surgery were 7.5(0.5) and 7.2(0.7) per cent respectively<sup>24,26,31–33</sup>. Two studies<sup>31,33</sup> found an increase in HbA1c concentration during the first 3 months after surgery, although stabilization was seen afterwards. During the first year after surgery, HbA1c levels were increased in both benign and malignant diseases, after which the levels remained stable at acceptable levels<sup>6</sup>. For endocrine-related reasons, 45 of 242 patients (18.6 per cent) were admitted to hospital<sup>2,18,19,21,23,26,27,32,35</sup>.

Two studies<sup>21,29</sup> reported on long-term diabetes-related complications. Crippa and colleagues<sup>21</sup> reported long-term diabetes-related complications in six of 45 patients after total pancreatectomy (follow-up at least 60 months), including peripheral vascular disease (4 patients), stroke (1) and retinopathy (1). During a median follow-up of 2 years, Parsaik *et al.*<sup>29</sup> found development of target organ complications in seven of 26 patients.

Nine studies<sup>2,18,19,21,22,24,31,32,35</sup> described diabetes-related mortality, which occurred in six of 365 patients (1.6 per cent). Three patients died from hypoglycaemia, two

after 8 and 22 months, and one patient at an unknown time during a median follow-up of 35 (range 4–168) months. Two patients died from ketoacidosis, one patient after 5 months and the other at an unknown time during a median follow-up of 21 (2–222) months. Hyperglycaemia was the cause of death in one patient 17 days after surgery. In addition, diabetes-related mortality was 0 per cent (0 of 94 patients) in the most recent series, comprising the studies that included patients treated after 2005<sup>19,22,31</sup> (Table 2).

## Exocrine insufficiency

Outcomes related to exocrine insufficiency were reported in 15 studies<sup>2,6,18,19,21,24–27,29,31–35</sup>, including 495 patients, during a median follow-up of 19.6 (range 1.5–96.0) months (Table 3). Exocrine insufficiency-related symptoms were reported by 43.5 per cent (143 of 329 patients) during a median follow-up of 15.9 (1.5–96.0) months. Among 136 patients receiving pancreatic enzyme substitution, 32 (23.5 per cent) still reported symptoms<sup>18,21,33,35</sup>. In general, the most common symptom was diarrhoea, which occurred in 0–64 per cent of the patients<sup>2,18,21,33–35</sup>. Steatorrhoea was described by two studies<sup>21,26</sup>, varying between 14 and 27 per cent of patients. Ten studies<sup>18,19,21,24,27,29,32–35</sup> reported on loss of bodyweight after surgery, with an occurrence of 44–85 per cent of the patients and a median loss of 6.7 (range 3.1–15) kg. Shi and co-workers<sup>31</sup> observed stabilization of

Table 2 Endocrine insufficiency in patients who had a total pancreatectomy							
Reference	n	Follow-up (months)*	Insulin (units/day)*	Glycaemic events/week*	Complications	Hospitalization	Mortality
Barbier et al. <sup>18</sup>	52	35 (4–168)	R: 21 (7–70)	n.r.	n.r.	Hypoglycaemic coma (6)	Ketoacidosis (1)
			L: 16 (7–48)				Hypoglycaemia (1)
Subgroup	25	66 (7–168)	n.r.	10 (1–36)/month	Loss of consciousness due to hypoglycaemia (10)	Diabetes equilibration (14)	n.r.
Casadei et al. <sup>19</sup>	13	23 (6–60)	R: 18 (0–18)	4 (1–10) hypoglycaemia and hyperglycaemia	n.r.	Poor glycaemic control (3)	Severe hypoglycaemia (0)
			L: 7 (4–20)				
Casadei et al. <sup>20</sup>	35	> 1 year	R: 7 (0–18) I: 3 (0–19) L: 19 (4–40)	n.r.	n.r.	n.r.	n.r.
Crippa et al. <sup>21</sup>	45	2–14 years	32 (18–52)	2 (0–5)	PVD (4) Stroke (1) Retinopathy (1)	Hyperglycaemia (3) Hypoglycaemia (7)	Hypoglycaemia (0)
Crippa et al. <sup>22</sup>	29	62 (6–91)	n.r.	n.r.	n.r.	n.r.	Insulin-related coma (0)
Subgroup	15	63 (30–91)	R: 25 (19–38) L: 4 (0–14)	n.r.	Severe hypoglycaemia (7)	n.r.	n.r.
Epelboym et al. <sup>23</sup>	17	40.3 (i.q.r. 32.8)	29.8(18.6)†	2 (i.q.r. 2)	Hypoglycaemic episodes (16)	Hypoglycaemic episodes (4)	n.r.
Fujino et al. <sup>24</sup>	36	n.r.	22(6)†	n.r.	n.r.	n.r.	Severe hypoglycaemia (2)
Hartwig et al. <sup>6</sup>	83	≥ 1 year	n.r.	n.r.	n.r.	n.r.	n.r.
Jamil et al. <sup>26</sup>	14	Up to 24	Insulin pump (n = 3)	n.r.	Hypoglycaemic episodes (7)	Hypoglycaemia (1) Hyperglycaemia (0)	n.r.
Kitagawa et al. <sup>27</sup>	10	7.9 (2.1–28.6)	0.45(0.13) units/kg/day‡ at discharge†	n.r.	n.r.	Hypoglycaemia (1)	n.r.
Müller et al. <sup>2</sup>	47	> 6 after surgery	n.r.	n.r.	n.r.	Hyperglycaemia (4) Hypoglycaemia (3)	Mortality (0)
Nikfarjam et al. <sup>28</sup>	15	Postoperative period	n.r.	n.r.	Hypoglycaemia (4)	n.r.	n.r.
Parsaik et al. <sup>29</sup>	26	2 (i.q.r. 0.6–5.3) years	n.r.	n.r.	Mild hypoglycaemic episodes (19) Severe hypoglycaemic episodes (7) Target organ complications (7)	n.r.	n.r.
Reddy et al. <sup>30</sup>	100	Postoperative period	n.r.	n.r.	Glycaemic control: CD I (20), CD IV (1)	n.r.	n.r.
Shi et al. <sup>31</sup>	52	To 12 months after surgery	0.56(0.12) units/kg/day‡ at 12 months†	n.r.	n.r.	n.r.	Hypoglycaemia or diabetic complications (0)

Table 2 Continued							
Reference	n	Follow-up (months)*	Insulin (units/day)*	Glycaemic events/week*	Complications	Hospitalization	Mortality
<b>Stauffer et al.</b> <sup>32</sup>	47	Postoperative period	L: 10 (0–80) at discharge	n.r.	Major glycaemic events (2)	n.r.	Hyperglycaemia (1)
Subgroup	46	To 12 months after surgery	n.r.	n.r.	n.r.	Glycaemic events (5)	n.r.
<b>Suzuki et al.</b> <sup>33</sup>	41	To 12 months after surgery	30 (12–50)	n.r.	n.r.	n.r.	n.r.
			0.56(0.16) units/kg/day at 12 months†				
<b>Watanabe et al.</b> <sup>35</sup>	44	21 (2–222)	n.r.	n.r.	n.r.	n.r.	Ketoacidosis (1)
Subgroup	25	22 (2–73)	R: 17 (10–28)	2 (1–4) (12 patients)	Loss of consciousness (0)	Hyperglycaemia or hypoglycaemia (0)	n.r.
			L: 6 (0–16)				
<b>Zakaria et al.</b> <sup>36</sup>	103	Postoperative period	n.r.	n.r.	Major glycaemic event (6)	n.r.	n.r.
<b>Overall</b> ¶	809	20.8 months§	26†§	2.3 (2–4) (125 patients)§	112 of 432 (25.9)	45 of 242 (18.6)	6 of 365 (1.6)
			R: 16				
			L: 12				

Values are \*median (range) and †mean(s.d.). ‡Not used in the analysis. §Weighted average of medians. ¶Values in parentheses are percentages unless indicated otherwise. R, rapid-acting insulin; n.r., not reported; L, long-acting insulin; I, intermediate-acting insulin; PVD, peripheral vascular disease; CD, Clavien–Dindo co-morbidity grade.

postoperative weight loss after 6–12 months of follow-up. One study<sup>33</sup> reported the dosages of pancreatic enzymes during the first year after operation and revealed that patients needed higher dosages as time progressed. In that study, pancreatic enzyme dosage was based on patients' stool consistency, BMI, serum albumin and signs of liver steatosis on CT, achieving a stable BMI and no diarrhoea.

Several studies<sup>6,18,24,25,31,33,34</sup> investigated laboratory tests to assess patients' nutritional status. Serum nutritional markers decreased in the first 1–6 months after total pancreatectomy, but had stabilized or normalized by 12 months after surgery<sup>6,24,31,33,34</sup>. Barbier and colleagues<sup>18</sup> showed that, also in the long term, prealbumin and albumin levels remained stable within normal ranges.

Hata *et al.*<sup>25</sup> investigated long-term consequences by describing development of hepatic steatosis in 16 of 43 patients, which was associated with poor nutritional status early after surgery. None of these patients developed liver cirrhosis or liver failure during long-term follow-up. Suzuki and co-workers<sup>33</sup> suggested that all patients tended to develop hepatic steatosis at 1 year after surgery, but signs of steatosis decreased by enhancing the dose of pancreatic enzymes. Liver function also remained normal in the long term (median follow-up 66 months), according to Barbier *et al.*<sup>18</sup>.

## Quality of life

QoL after total pancreatectomy for all indications was reported in seven studies<sup>2,6,18–20,23,35</sup>, including 243 patients, using various validated questionnaires. The median weighted follow-up in these studies was 28.6 (range 6.0–66.0) months. The following questionnaires were used: EORTC QLQ-C30 (5 studies<sup>2,6,18,19,23</sup>), EORTC QLQ after pancreatic resection (EORTC QLQ-PAN26) (3 studies)<sup>6,18,23</sup>, Audit of Diabetes Dependent Quality of Life (ADD-QoL) (1 study<sup>23</sup>), Short Form 36 (SF-36) (1 study<sup>35</sup>), Problem Areas in Diabetes scale (PAID20) (1 study<sup>20</sup>) and EQ-5D-5L (1 study<sup>20</sup>).

The EORTC QLQ-C30 questionnaire, designed to measure overall health status in patients with cancer<sup>37</sup>, was used in four studies<sup>2,18,19,23</sup>, including 102 patients. One study<sup>6</sup> with 81 patients was excluded for this analysis, because EORTC QLQ-C30 scores were shown only in figures and no exact data were available. The mean global health status score was 64 per cent, a small clinically important difference (58–69 per cent) compared with the general population score of 71 per cent (Table 4). Mean scores in the functioning scales varied from 67 to 78 per cent and, compared with the general population scores, they varied from 9 per cent (little change) to 14 per cent (moderate change). Global health status and all

**Table 3 Exocrine insufficiency in patients who had a total pancreatectomy**

Reference	n	Follow-up (months)*	Pancreatic lipase (units/day)*	Symptoms and related readmissions	Weight loss	
					No. of patients	kg*
Barbier <i>et al.</i> <sup>18</sup>	25	66 (7–168)	150 000 (75 000–450 000) 6 (3–18) capsules	Diarrhoea (6)	15	9 (2–14)
Casadei <i>et al.</i> <sup>19</sup>	13	23 (6–60)	8 (6–11) capsules	n.r.	11	15 (1–32)
Crippa <i>et al.</i> <sup>21</sup>	45	2–14 years	80 000 (30 000–160 000)	Steatorrhoea (12) Diarrhoea (6)	20	5 (1–18)
Fujino <i>et al.</i> <sup>24</sup>	n.r.	> 12	n.r.	n.r.	n.r.	8.8(10.4)%
Hartwig <i>et al.</i> <sup>6</sup>	75	≥ 1 year	n.r.	n.r.	n.r.	n.r.
Hata <i>et al.</i> <sup>25</sup>	43	> 6	18 patients: high dose (1800 mg/day) Pancrelipase within 2 weeks of TP	Hepatic steatosis (16)	n.r.	n.r.
Jamil <i>et al.</i> <sup>26</sup>	14	≥ 24	n.r.	Steatorrhoea because of intolerance to medication (1) Inadequate dosing (1)	n.r.	n.r.
Kitagawa <i>et al.</i> <sup>27</sup>	10	7.9 (2.1–28.6)	n.r.	Readmission because of diarrhoea (1) Use of antidiarrhoeal drugs (4)	n.r.	4.1†
Müller <i>et al.</i> <sup>2</sup>	47	> 6	n.r.	Flatulence (28) Diarrhoea (30)	n.r.	n.r.
Parsaik <i>et al.</i> <sup>29</sup>	26	2 (i.q.r. 0.6–5.3) years	n.r.	n.r.	n.r.	3.1(0.54)†
Shi <i>et al.</i> <sup>31</sup>	52	To 12 months after surgery	n.r.	n.r.	n.r.	n.r.
Stauffer <i>et al.</i> <sup>32</sup>	46	To 12 months after surgery	n.r.	Readmission because of malnutrition, failure to thrive, nausea, vomiting, diarrhoea or weakness (20)	n.r.	8.8 (1.2–39.5)
Suzuki <i>et al.</i> <sup>33</sup>	41	To 12 months after surgery	125 145(97 487) at 12 months†	Diarrhoea (0)	18	4.23
Takami <i>et al.</i> <sup>34</sup>	33	Early postoperative period	n.r.	Severe diarrhoea (10) Dumping syndrome (0)	n.r.	> 10% at 6 months
Watanabe <i>et al.</i> <sup>35</sup>	25	22 (2–73)	150 000 (0–225 000)	Diarrhoea (8)	17	4.5 (1–15)
Overall‡	495	19.6‡		143 of 329 (43.5)	81 of 149 (54.4)	6.7 (3.1–15)‡

Values are \*median (range) and †mean(s.d.); ‡values in parentheses are percentages. ‡Weighted average of medians. n.r., Not reported; TP, total pancreatectomy.

functioning domains differed significantly in comparison with those for the general population. Mean scores in the symptom scales varied from 6 to 38 per cent, with fatigue, dyspnoea and especially diarrhoea as the main symptoms.

Long-term QoL was evaluated in 81 patients by Hartwig and colleagues<sup>6</sup>, using the EORTC QLQ-C30. After matching data with an age- and sex-matched healthy control population, no differences in global health status were found. During the first year after surgery, global health status was significantly lower in patients with benign disease, but no differences between benign and malignant disease were seen after this time. Patients with malignant disease

suffered significantly more from diarrhoea than those with benign disease, compared with the control population.

The EORTC QLQ-PAN26 questionnaire, designed to evaluate disease symptoms, treatment side-effects and emotional issues specific to pancreatic cancer, was used in three studies<sup>6,18,23</sup> (67 patients). The most frequently described symptom was altered bowel habit.

One study<sup>35</sup> with 25 patients used the SF-36, a questionnaire that evaluates eight domains of physical and mental well-being. The physical aspects of QoL were significantly lower than those in the national population (which included many young people) ( $P < 0.050$ ). In addition,



Table 4 Quality of life assessed with the EORTC QLQ-C30 questionnaire

	Barbier <i>et al.</i> <sup>18</sup> (n = 25) <sup>¶</sup>	Casadei <i>et al.</i> <sup>19</sup> (n = 13)	Epelboym <i>et al.</i> <sup>23</sup> (n = 17)	Müller <i>et al.</i> <sup>2</sup> (n = 47)	Total (n = 102)	General population <sup>38</sup> (n = 7802)	P#	Clinically relevant difference (%) <sup>1,4</sup>
<b>Global health status*</b>	64(4)	58(21)	69(n.r.)	n.r.	64(13)	71(22)	0.019	7 (low)
<b>Functioning scales†</b>	n.r.	n.r.	79(n.r.)	n.r.	79	n.r.		
Physical	84(3)	65(25)	n.r.	n.r.	78(17)	90(16)	<0.001	12 (moderate)
Role	75(2)	67(25)	n.r.	n.r.	72(15)	85(25)	0.001	13 (moderate)
Emotional	76(3)	67(21)	n.r.	63(24)	67(11)	76(23)	<0.001	9 (low)
Cognitive	76(2)	75(25)	n.r.	n.r.	76(15)	86(20)	0.002	10 (moderate)
Social	73(2)	75(25)	n.r.	n.r.	74(15)	88(23)	<0.001	14 (moderate)
<b>Symptom scales‡</b>	n.r.	n.r.	18(n.r.)	n.r.	18	n.r.		
Fatigue	38(3)	39(22)	n.r.	n.r.	38(13)	24(24)	<0.001	14 (moderate)
Nausea and vomiting	15(2)	17(17)	n.r.	n.r.	16(10)	4(12)	<0.001	12 (moderate)
Pain	26(2)	21(21)	n.r.	n.r.	24(13)	21(28)	0.509	3 (none)
Dyspnoea	19(1)	42(25)	n.r.	n.r.	27(18)	12(23)	<0.001	15 (moderate)
Insomnia	20(1)	42(25)	n.r.	n.r.	28(18)	22(30)	0.218	6 (low)
Appetite loss	13(1)	25(25)	n.r.	n.r.	17(16)	7(18)	<0.001	10 (moderate)
Constipation	9(1)	8(8)	n.r.	4.2(17)	6(13)	7(18)	0.646	1 (none)
Diarrhoea	25(1)	33(17)	n.r.	n.r.	28(11)	7(18)	<0.001	21 (high)
<b>Financial difficulties</b>	16(1)	0(0)	n.r.	n.r.	11(8)	10(23)	0.789	1 (none)
<b>EORTC QLQ-C30 summary score§</b>	78	71	n.a.	n.a.	76	86	0.004	11 (moderate)

Values are mean(s.d.). n.r., Not reported; n.a., not applicable. \*The higher the score, the better the global health status; †the higher the score, the better the functioning; ‡the higher the score, the greater the symptoms. §(Physical functioning + Role functioning + Social functioning + Emotional functioning + Cognitive functioning + (100 – Fatigue) + (100 – Pain) + (100 – Nausea and Vomiting) + (100 – Dyspnoea) + (100 – Insomnia) + (100 – Appetite loss) + (100 – Constipation) + (100 – Diarrhoea))/13. ¶Data received from corresponding author. #Student's *t* test.

scores of vitality and mental well-being were significantly worse in patients with diarrhoea-related complaints. However, QoL was comparable with that in age-matched controls. These authors concluded that QoL after total pancreatectomy is acceptable if the patient is capable of self-management.

#### Diabetes-specific quality of life

Epelboym and colleagues<sup>23</sup> assessed the impact of diabetes on the QoL in 17 patients after total pancreatectomy and in eight patients following pancreatoduodenectomy. Insulin was used in all patients in the total pancreatectomy group *versus* half of those in the pancreatoduodenectomy group. All average weighted scores, measured by the ADD-QoL questionnaire, did not differ significantly between the groups. However, leisure time and physical activity were lower in patients after total pancreatectomy. These authors concluded that total pancreatectomy-induced diabetes has a negative impact on functioning and activities, and that overall QoL is comparable with that in patients who have had a pancreatoduodenectomy.

One study<sup>20</sup> used the PAID20 questionnaire in 35 patients after total pancreatectomy and in 43 after pancreatoduodenectomy, and did not find any significant differences, except for the question about feelings of guilt

or anxiety about their diabetes management when glucose values were off-track. These authors concluded that diabetes after total pancreatectomy is manageable, with acceptable QoL.

#### Quality of life after pancreatoduodenectomy versus total pancreatectomy

Two studies<sup>20,23</sup> compared QoL after total pancreatectomy with that following pancreatoduodenectomy. Epelboym *et al.*<sup>23</sup> performed a matched-paired analysis of age, postoperative pathology, and preoperative and postoperative presence of diabetes. After a median follow-up of 45 months, patients in both groups had similar functional and symptom scales and global health status. Overall QoL after total pancreatectomy was good, and showed no significant difference from that in patients who had a pancreatoduodenectomy, according to Casadei and colleagues<sup>20</sup>. Diabetes impacted poorly on QoL in both groups, but the overall PAID20 score tended to favour pancreatoduodenectomy ( $P=0.081$ ). Nevertheless, Casadei *et al.*<sup>20</sup> concluded that overall QoL and the impact of diabetes after total pancreatectomy were acceptable, and comparable with those following pancreatoduodenectomy.

## Discussion

This systematic review of 1536 patients after total pancreatectomy has shown that, over a follow-up period of 20–8 months, endocrine-related readmission was fairly common (18.6 per cent) and should be improved. Diabetes-related mortality (1.6 per cent) did occur, but only in patients treated before 2005. The burden of diarrhoea seems to be significant, with a negative impact on QoL, requiring accurate personalized management. Although overall QoL appears acceptably reduced after total pancreatectomy, data are sparse as few studies have reported on long-term endocrine and exocrine insufficiency and QoL.

Most surgeons favour partial over total pancreatectomy in order to prevent the consequences of insulin-dependent diabetes and its effects on QoL. Based on this information, new-onset diabetes after total pancreatectomy seems similar to type 1 diabetes mellitus<sup>26,39,40</sup>. Multiple studies<sup>2,20,26,35,39,41</sup> concluded that diabetes after total pancreatectomy could be managed well, whereas others<sup>18,19</sup> still emphasized its complexity. The present review revealed a substantial rate of diabetes-related morbidity, but nevertheless acceptable and stabilized levels of HbA1c in the first year after surgery, indicating reasonable management. All diabetes-related mortality occurred in studies that included patients between 1990 and 2013. More recent studies, which included patients treated only after 2005, did not report any diabetes-related mortality at all. Hence, brittle diabetes may no longer be a correct term in current practice of total pancreatectomy, owing to improved diabetes management.

Diarrhoea was the most frequently reported symptom after total pancreatectomy; 23.5 per cent of patients still had symptoms despite pancreatic enzyme substitution. The wide range of incidence of diarrhoea (0–64 per cent) suggests that management is difficult, but achievable. In the literature<sup>6,18,25</sup>, the extent of resection is mentioned as a contributing cause of diarrhoea. Extended resection could lead to autonomic denervation and therefore impaired bowel control, explaining the difference in severity of diarrhoea between benign and malignant indications<sup>2,6</sup>. Nevertheless, the potential for sufficient stool management and improvement of nutritional status over time suggests a crucial role for extensive patient education and follow-up to optimize pancreatic enzyme replacement therapy<sup>18,33,42</sup>. Moreover, optimal nutritional status seems to be important to reduce the risk of hepatic steatosis<sup>25,33</sup>. In 1991, Dresler *et al.*<sup>43</sup> found that three of 49 patients died as consequence of liver cirrhosis, but cirrhosis was no longer seen in recent literature.

In this review, QoL was reduced significantly in 11 of 15 domains in comparison with that in the general population. Decreases in global health status and functioning were classified as small and moderate, indicating a reasonable reduction. Specifically, two studies<sup>6,35</sup> compared QoL with age- and/or sex-matched healthy individuals and found no significant differences during a median follow-up of 22 (range 2–73) months and up to 5 years respectively. Other studies, including some not in the present systematic review, described impaired but still acceptable QoL, and even comparability with other types of diabetes and partial pancreatectomy<sup>2,18,20,23,40,41,44,45</sup>. Whereas the impact of diabetes on QoL is suggested to be comparable with that of partial pancreatoduodenectomy<sup>20,23</sup>, several articles<sup>2,6,18,35</sup> mentioned the major impact of diarrhoea.

The current state of knowledge about functional outcomes after total pancreatectomy and its impact on QoL seems to be limited, and a variety of opinions exist concerning the acceptability of outcomes. Nevertheless, recent studies<sup>1,18,36</sup> have shown an increase in total pancreatectomy performed over time, especially in patients with IPMN. In the present review, however, the majority of patients (52.5 per cent) underwent total pancreatectomy for PDAC and 29.6 per cent for IPMN. Despite the potential benefits of total pancreatectomy as radical treatment for IPMN, international consensus regarding the role of total pancreatectomy is lacking, possibly as result of limited data on functional outcomes, QoL and long-term survival rates compared with those for partial pancreatectomy<sup>8</sup>.

This review should be interpreted in the light of some shortcomings. First, the heterogeneity between studies was substantial, mainly because of different indications for total pancreatectomy. Second, follow-up periods varied (from 1 month to several years). Long-term follow-up was limited, and therefore data on long-term consequences of total pancreatectomy are sparse. In addition, one-third of all included studies made no distinction between elective and emergency total pancreatectomy. Potentially, outcomes of (completion) total pancreatectomy in emergency settings may have influenced outcomes negatively. A strength of this review is that studies with relative small cohorts and dated series were excluded.

Several further studies are needed in this field. First, few studies of long-term outcomes on endocrine and exocrine insufficiency and QoL have been published, and this needs to be investigated in large prospective series, evaluating clinicophysiological parameters and their courses over time. Second, such studies should compare outcomes with those following partial pancreatectomy, especially for IPMN. Third, evidence-based guidelines

are needed for optimal management of endocrine and exocrine insufficiency.

### Acknowledgements

L.S. and T.F.S. contributed equally to this publication.

The authors acknowledge the work of F. S. van Etten (clinical librarian) for her help with the literature search.

L.S. has received a grant from ZEALAND for studies on management of postpancreatectomy diabetes. M.G.B. has received a grant (number UVA2013-5842) from the Dutch Cancer Society for studies on pancreatic cancer.

*Disclosure:* The authors declare no conflict of interest.

### References

- Almond M, Rob KJ, Hodson J, Sutcliffe R, Marudanayagam R, Isaac J *et al.* Changing indications for a total pancreatectomy: perspectives over a quarter of a century. *HPB (Oxford)* 2015; **17**: 416–421.
- Müller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U *et al.* Is there still a role for total pancreatectomy? *Ann Surg* 2007; **246**: 966–975.
- Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ, Raimondo M *et al.* Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. *Gastroenterology* 2002; **123**: 1500–1507.
- Andrén-Sandberg A, Ansoorge C, Yadav TD. Are there indications for total pancreatectomy in 2016? *Dig Surg* 2016; **33**: 329–334.
- Del Chiaro M, Rangelova E, Segersvärd R, Arnelo U. Are there still indications for total pancreatectomy? *Updates Surg* 2016; **68**: 257–263.
- Hartwig W, Gluth A, Hinz U, Bergmann F, Spronk PE, Hackert T *et al.* Total pancreatectomy for primary pancreatic neoplasms: renaissance of an unpopular operation. *Ann Surg* 2015; **261**: 537–546.
- Griffin JF, Poruk KE, Wolfgang CL. Is it time to expand the role of total pancreatectomy for IPMN? *Dig Surg* 2016; **33**: 335–342.
- Scholten L, van Huijgevoort NCM, Bruno MJ, Fernandez-Del Castillo C, Satoi S, Sauvanet A *et al.*; European Study Group on Cystic Tumours of the Pancreas and the International Association of Pancreatology. Surgical management of intraductal papillary mucinous neoplasm with main duct involvement: an international expert survey and case-vignette study. *Surgery* 2018; doi:10.1016/j.surg.2018.01.025 [Epub ahead of print].
- Scholten L. *PROSPERO – International Prospective Register of Systematic Reviews*. [http://www.crd.york.ac.uk/PROSPERO/display\\_record.php?ID=CRD420016051093](http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD420016051093) [accessed November 2018].
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009; **62**: e1–e34.
- Suzuki S, Kajiyama H, Takemura A, Shimazaki J, Nishida K, Shimoda M. The clinical outcomes after total pancreatectomy. *Dig Surg* 2017; **34**: 142–150.
- WHO. *Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus*; 1999. [http://apps.who.int/iris/bitstream/10665/66040/1/WHO\\_NCD\\_NCS\\_99.2.pdf](http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf) [accessed 2 February 2018].
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2016; **39**(Suppl 1): S13–S22.
- Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 1998; **16**: 139–144.
- Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M *et al.*; The Ottawa Hospital Research Institute. *The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of NonRandomised Studies in Meta-Analyses*. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) [accessed 15 February 2018].
- Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014; **14**: 135.
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005; **5**: 13.
- Barbier L, Jamal W, Dokmak S, Aussilhou B, Corcos O, Ruszniewski P *et al.* Impact of total pancreatectomy: short- and long-term assessment. *HPB (Oxford)* 2013; **15**: 882–892.
- Casadei R, Monari F, Buscemi S, Laterza M, Ricci C, Rega D *et al.* Total pancreatectomy: indications, operative technique, and results: a single centre experience and review of literature. *Updates Surg* 2010; **62**: 41–46.
- Casadei R, Ricci C, Taffurelli G, Guariniello A, Di Gioia A, Di Marco M *et al.* Is total pancreatectomy as feasible, safe, efficacious, and cost-effective as pancreaticoduodenectomy? A single center, prospective, observational study. *J Gastrointest Surg* 2016; **20**: 1595–1607.
- Crippa S, Tamburrino D, Partelli S, Salvia R, Germani S, Bassi C *et al.* Total pancreatectomy: indications, different timing, and perioperative and long-term outcomes. *Surgery* 2011; **149**: 79–86.
- Crippa S, Pergolini I, Rubini C, Castelli P, Partelli S, Zardini C *et al.* Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. *Surgery* 2016; **159**: 1041–1049.
- Epelboym I, Winner M, DiNorcia J, Lee MK, Lee JA, Schrope B *et al.* Quality of life in patients after total pancreatectomy is comparable with quality of life in patients who undergo a partial pancreatic resection. *J Surg Res* 2014; **187**: 189–196.

- 24 Fujino Y, Matsumoto I, Ajiki T, Kuroda Y. Clinical reappraisal of total pancreatectomy for pancreatic disease. *Hepatogastroenterology* 2009; **56**: 1525–1528.
- 25 Hata T, Ishida M, Motoi F, Sakata N, Yoshimatsu G, Naitoh T *et al.* Clinical characteristics and risk factors for the development of postoperative hepatic steatosis after total pancreatectomy. *Pancreas* 2016; **45**: 362–369.
- 26 Jamil LH, Chindris AM, Gill KR, Scimeca D, Stauffer JA, Heckman MG *et al.* Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: an exploratory study. *HPB Surg* 2012; **2012**: 381328.
- 27 Kitagawa M, Ikoma H, Ochiai T, Ishii H, Shiozaki A, Kuriu Y *et al.* Total pancreatectomy for pancreatic carcinoma: evaluation of safety and efficacy. *Hepatogastroenterology* 2012; **59**: 907–910.
- 28 Nikfarjam M, Low N, Weinberg L, Chia PH, He H, Christophi C. Total pancreatectomy for the treatment of pancreatic neoplasms. *ANZ J Surg* 2014; **84**: 823–826.
- 29 Parsaik AK, Murad MH, Sathananthan A, Moorthy V, Erwin PJ, Chari S *et al.* Metabolic and target organ outcomes after total pancreatectomy: Mayo Clinic experience and meta-analysis of the literature. *Clin Endocrinol (Oxf)* 2010; **73**: 723–731.
- 30 Reddy S, Wolfgang CL, Cameron JL, Eckhauser F, Choti MA, Schulick RD *et al.* Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. *Ann Surg* 2009; **250**: 282–287.
- 31 Shi HJ, Jin C, Fu DL. Impact of postoperative glycemic control and nutritional status on clinical outcomes after total pancreatectomy. *World J Gastroenterol* 2017; **23**: 265–274.
- 32 Stauffer JA, Nguyen JH, Heckman MG, Grewal MS, Dougherty M, Gill KR *et al.* Patient outcomes after total pancreatectomy: a single centre contemporary experience. *HPB (Oxford)* 2009; **11**: 483–492.
- 33 Suzuki S, Miura J, Shimizu K, Tokushige K, Uchigata Y, Yamamoto M. Clinicophysiological outcomes after total pancreatectomy. *Scand J Gastroenterol* 2016; **51**: 1526–1531.
- 34 Takami H, Fujii T, Kanda M, Suenaga M, Yamamura K, Kodera Y. Preservation of the pyloric ring confers little benefit in patients undergoing total pancreatectomy. *World J Surg* 2014; **38**: 1807–1813.
- 35 Watanabe Y, Ohtsuka T, Matsunaga T, Kimura H, Tamura K, Ideno N *et al.* Long-term outcomes after total pancreatectomy: special reference to survivors' living conditions and quality of life. *World J Surg* 2015; **39**: 1231–1239.
- 36 Zakaria HM, Stauffer JA, Raimondo M, Woodward TA, Wallace MB, Asbun HJ. Total pancreatectomy: short- and long-term outcomes at a high-volume pancreas center. *World J Gastrointest Surg* 2016; **8**: 634–642.
- 37 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ *et al.* The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993; **85**: 365–376.
- 38 Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M *et al.*; EORTC Quality of Life Group. *EORTC QLQ-C30 Reference Values*. EORTC: Brussels, 2008.
- 39 Jethwa P, Sodergren M, Lala A, Webber J, Buckels JA, Bramhall SR *et al.* Diabetic control after total pancreatectomy. *Dig Liver Dis* 2006; **38**: 415–419.
- 40 Roberts KJ, Blanco G, Webber J, Marudanayagam R, Sutcliffe RP, Muiesan P *et al.* How severe is diabetes after total pancreatectomy? A case-matched analysis. *HPB (Oxford)* 2014; **16**: 814–821.
- 41 Wu W, Dodson R, Makary MA, Weiss MJ, Hirose K, Cameron JL *et al.* A contemporary evaluation of the cause of death and long-term quality of life after total pancreatectomy. *World J Surg* 2016; **40**: 2513–2518.
- 42 Struyvenberg MR, Fong ZV, Martin CR, Tseng JF, Clancy TE, Fernández-Del Castillo C *et al.* Impact of treatments on diabetic control and gastrointestinal symptoms after total pancreatectomy. *Pancreas* 2017; **46**: 1188–1195.
- 43 Dresler CM, Fortner JG, McDermott K, Bajorunas DR. Metabolic consequences of (regional) total pancreatectomy. *Ann Surg* 1991; **214**: 131–140.
- 44 Belyaev O, Herzog T, Chromik AM, Meurer K, Uhl W. Early and late postoperative changes in the quality of life after pancreatic surgery. *Langenbecks Arch Surg* 2013; **398**: 547–555.
- 45 Billings BJ, Christein JD, Harmsen WS, Harrington JR, Chari ST, Que FG *et al.* Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? *J Gastrointest Surg* 2005; **9**: 1059–1067.

### Supporting information

Additional supporting information can be found online in the Supporting Information section at the end of the article.